Elevated thyroid autoantibodies as risk factors for metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus
2024

Thyroid Autoantibodies and Fatty Liver Disease in Diabetes

Sample size: 432 publication 10 minutes Evidence: high

Author Information

Author(s): Wu Wenchang, Yang Ziyi, Li Owen, Gan Lulu, Gao Yue, Xiang Cheng, Li Ling, Yan Yimin

Primary Institution: Wuhan University of Science and Technology

Hypothesis

This study aims to explore the relationship between thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with type 2 diabetes mellitus (T2DM).

Conclusion

Elevated TSH and TPOAb levels are risk factors for MAFLD in T2DM patients.

Supporting Evidence

  • 73.46% of MAFLD patients were overweight or obese.
  • MAFLD prevalence was positively correlated with TgAb and TPOAb levels.
  • Elevated TSH and TPOAb levels were identified as significant risk factors for MAFLD.

Takeaway

This study found that people with diabetes and fatty liver disease often have higher levels of certain thyroid antibodies, which might make their liver problems worse.

Methodology

The study included 534 T2DM patients, with 432 meeting the criteria after exclusions, and analyzed their thyroid function and antibody levels in relation to MAFLD.

Potential Biases

Potential confounding from unmeasured factors cannot be ruled out.

Limitations

The cross-sectional design limits causal inference, and there may be selection bias affecting generalizability.

Participant Demographics

The average age of participants was 54.65 years, with 60.3% male and 39.7% female.

Statistical Information

P-Value

P<0.001 for TSH and TPOAb as risk factors.

Confidence Interval

95% CI: 1.213-1.712 for TPOAb

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fendo.2024.1478818

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication